Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: ...
TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...
Unusual total active option classes on open include: Disney ( DIS ), Advance Auto Parts ( AAP ), TG Therapeutics ( TGTX ), MGM Resorts (MGM), ARK Genomic Revolution Multi Sector ETF ( ARKG ), Direxion ...
On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent ...
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript November 10, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 ...
In August 2024, TG Therapeutics announced that the FDA has cleared an investigational new drug (IND) application submitted by TG Therapeutics for azercabtagene zapreleucel (azer-cel), an ...
CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus ...
Dr. Hao has held similar roles at multiple biotechnology companies, including Vesigen Therapeutics, Codiak BioSciences, TG ...
US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic lymphocytic leukaemia, in a challenge to Roche. The New York-based firm has requested ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback